# OnCo record lisocabtagene-maraleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lisocabtagene-maraleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lisocabtagene-maraleucel" ;
  schema:name "Lisocabtagene maraleucel"@en ;
  schema:description "Lisocabtagene maraleucel is the only CAR-T approved for chronic lymphocytic leukaemia, for patients whose disease has outrun both BTK and BCL-2 inhibitors."@en ;
  schema:url <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lisocabtagene_maraleucel> ;
  owl:sameAs <http://www.wikidata.org/entity/Q105605102> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lisocabtagene%20maraleucel> ;
  onco:status "approved" ;
  onco:modality "CAR-T (CD19, defined CD4:CD8)" ;
  schema:alternateName "Breyanzi" ;
  onco:approval "US 2021: Relapsed/refractory LBCL after ≥2 lines", "US 2022: Second-line LBCL (TRANSFORM)", "US 2024: Relapsed/refractory CLL/SLL after BTK inhibitor and BCL-2 inhibitor (accelerated)" ;
  onco:acceleratedApproval "US 2024-03-21: Adult patients with relapsed/ refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least two prior lines of therapy including a Bruton’s tyrosine kinase (BTK) inhibitor and a B-cell lymphoma-2 (BCL-2) inhibitor", "US 2024-05-15: Adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy" ;
  onco:acceleratedApprovalConfirmed "US 2026-02-20: Adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll-relapsed/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/transcend-cll-004/>, <https://onco.cc/trials/nct07015242/> .